JCI Editorial Board
potential first-tier conflicts of interest

Updated April 28, 2026

Go to the JCI's conflict-of-interest policy

AbbVie (A.B. Heimberger, S.E. Quaggin)

AccureX (D. Krainc)

Alnylam (A.B. Heimberger)

Aplexis Inc. (P. Ji)

Biofluid Technology (E.M. McNally)

BioMed Central (H. Perlman)

Boehringer Ingelheim (G.D. Barish)

Borealis Biosciences (B.D. Humphreys)

Calidi Biotherapeutics (M.S. Lesniak)

Carbiogene Therapeutics Co. Ltd. (Y. Yang)

Caris Life Sciences (A.B. Heimberger)

Chinook Therapeutics (Novartis) (B.D. Humphreys)

Cloc Iniciativas Medicas (M. Hussain)

Degromics Bio, Inc. (S.A. Abdulkadir)

Gateway Biome (E.B. Chang)

Ikaika Therapeutics (E.M. McNally)

Inomagen Therapeutics (R. Arora)

Ionis (J. Bass)

Kardigan (E.M. McNally)

Lakeside Discovery (A. Shilatifard)

Leal Therapeutics (D. Krainc)

Leducq Foundation (H. Ardehali)

Lung Healing Technologies (A. Bharat)

Lung IQ LLC (A. Bharat)

Mannin Research Inc. (S.E. Quaggin)

Mediar Therapeutics (B.D. Humphreys)

Medtronic (J. Bass)

Moonlight Bio (J. Choi)

Nfold (S. Eisenbarth)

Novartis (E.M. McNally)

Oligo Foundry (E.M. McNally)

Omega Therapeutics (A. Shilatifard)

OrbiMed (D. Krainc)

PepGen (E.M. McNally)

Pfizer (N.S. Chandel)

Pyxis Oncology (M.L. Alegre)

Rafael Pharmaceuticals (N.S. Chandel)

Regeneron (J. Bass)

Riptide LLC (E.M. McNally)

Sera BioPharma (M.S. Lesniak)

Shanghai Henlius Biotech, Inc. (Y. Yang)

Tenaya Therapeutics (E.M. McNally)

Thermo Fisher Scientific (J. Bass)

Three Squared Biosciences (E.B. Chang)

Vanqua Bio (D. Krainc)

Vertex Pharmaceuticals (J. Bass)

Visiongate LLC (A. Bharat)

Vortex Therapeutics (S.A. Abdulkadir)